No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NKTR240719C1500
- 0.10
- +0.01+11.11%
15min DelayClose Jul 12 15:59 ET
0.15High0.10Low
0.10Open0.09Pre Close27 Volume14 Open Interest1.50Strike Price305.00Turnover165.74%IV12.68%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.4548Delta1.1951Gamma14.20Leverage Ratio-0.0095Theta0.0001Rho6.46Eff Leverage0.0008Vega
Intraday
- 5D
- Daily
News
Rodman & Renshaw Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $2
Rodman & Renshaw analyst Anthony Butler initiates coverage on $Nektar Therapeutics(NKTR.US)$ with a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success ra
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Oppenheimer analyst Jay Olson maintains $Nektar Therapeutics(NKTR.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 43.6% and a total average return of 16.3% over t
Nektar Therapeutics(NKTR.US) Director Sells US$23,400 in Common Stock
$Nektar Therapeutics(NKTR.US)$ Director CHESS ROBERT sold 19,500 shares of common stock on Jun 14, 2024 at an average price of $1.2 for a total value of $23,400.Source: Announcement What is statement
Express News | Nektar Therapeutics - Ind-Enabling Studies Underway for Nktr-0165 With First-in-Human Studies Planned in First Half of 2025
Express News | Nektar Therapeutics: Nktr-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism
Express News | Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024
Comments
$Nektar Therapeutics(NKTR.US$
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
$Nektar Therapeutics(NKTR.US$ why such a drop today?
$Nektar Therapeutics(NKTR.US$ raise ur hand if u bought this above 50dollars 😂😂😂
1
1
$Nektar Therapeutics(NKTR.US$ Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
1
$Nektar Therapeutics(NKTR.US$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
1
Read more